Cargando…

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

BACKGROUND: Hereditary angioedema (HAE) with C1‐inhibitor deficiency (HAE‐C1‐INH) is characterized by recurrent, debilitating episodes of swelling. Sebetralstat, an investigational oral plasma kallikrein inhibitor, demonstrated promising efficacy for on‐demand treatment of HAE‐C1‐INH in a phase 2 tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohn, Danny M., Aygören‐Pürsün, Emel, Bernstein, Jonathan A., Farkas, Henriette, Lumry, William R., Maurer, Marcus, Zanichelli, Andrea, Iverson, Matthew, Hao, James, Smith, Michael D., Yea, Christopher M., Audhya, Paul K., Riedl, Marc A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476273/ https://www.ncbi.nlm.nih.gov/pubmed/37746795 http://dx.doi.org/10.1002/clt2.12288

Ejemplares similares

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies
por: Gower, Richard G, et al.
Publicado: (2011)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
por: Aygören-Pürsün, Emel, et al.
Publicado: (2010)

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
por: Aygören-Pürsün, Emel, et al.
Publicado: (2018)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
por: Aygören-Pürsün, Emel, et al.
Publicado: (2016)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012)

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry()
por: Valerieva, Anna, et al.
Publicado: (2021)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
por: Farkas, Henriette, et al.
Publicado: (2011)

Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
por: Mendivil, Joan, et al.
Publicado: (2021)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Hereditary Angioedema: The Economics of Treatment of an Orphan Disease
por: Lumry, William Raymond
Publicado: (2018)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Home treatment with conestat alfa in attacks of hereditary angioedema due to C1-inhibitor deficiency
por: Farkas, Henriette, et al.
Publicado: (2015)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021)

Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Management of upper airway edema caused by hereditary angioedema
por: Farkas, Henriette
Publicado: (2010)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2020)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency
por: Veszeli, Nóra, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u4ov1fsmv5649oog0183v1m1pu